Biotechnology News and Research

RSS

Tobira Therapeutics presents data on TBR-652 at the European AIDS Conference

Tobira Therapeutics, a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two double-blind, placebo-controlled studies of TBR-652 in eighty-four healthy volunteers.

12 Nov 2009

AVMA confirms that a household cat in Iowa showed signs of H1N1 influenza

Amarillo Biosciences, Inc. reported that the American Veterinary Medical Association (AVMA) recently confirmed that a household cat in Iowa developed signs of respiratory infection caused by H1N1 influenza virus.

12 Nov 2009

Pacific Biosciences selects Camstar Manufacturing enterprise software to deliver innovative products

Camstar Systems, Inc. announced today that Pacific Biosciences, a leader in the development of a transformative Single Molecule Real Time (SMRT™) DNA sequencing platform, has selected the Camstar Manufacturing™ enterprise software platform to enable its critical transition from product development to high-volume production, and to ensure consistent top product quality.

12 Nov 2009

New biopharmaceutical business intelligence tool from Deloitte Recap

Deloitte Recap LLC (Recap) has launched "Development Optimizer," the third product in the Recap IQ Series by Deloitte. The series of biopharmaceutical business intelligence tools are part of a new subscription service tailored toward business development, corporate strategy, financial, clinical development, legal, academic and R&D professionals.

11 Nov 2009

UK research funders announce support for a series of H1N1 2009 research projects

Leading UK research funders today announce -7.5 million of funding for a series of projects aimed at understanding the development and spread of pandemic influenza H1N1 2009 - or 'swine flu'. The research will look at every aspect of the virus, on pig farms, in pig and human populations, and in hospital intensive care units.

11 Nov 2009

Vertex Pharmaceuticals announces exchange agreement with holders of its 4.75% Convertible Senior Subordinated Notes

Vertex Pharmaceuticals Incorporated announced today that holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $109.0 million in aggregate principal amount of those notes and accrued interest for approximately 4.8 million shares of the Company’s common stock, which is approximately 140,000 shares more than the number of shares into which the notes were convertible under their original terms.

11 Nov 2009

Biopharma leaders to discuss optimized clinical operations and outsourcing strategies at iiBIG's forum

iiBIG and the newly formed Global Biopharmaceutical Advisory Board have jointly planned an event that will focus on one of the most dynamic trends in the pharmaceutical, biotechnology, and medical device industries -- strategic outsourcing. Biopharma CEOs, VPs of Global Operations, and Department Heads will meet at the 4th Annual Global Clinical Trial Partnerships, March 1-2, 2010, in Princeton, New Jersey to discuss the latest strategies for optimizing global operations.

11 Nov 2009

Cambridge based hub to use DNA sequencing platforms for advancing its targeted medical resequencing studies

The University of Cambridge and Life Technologies Corporation, announced today the formation of a collaboration to advance translational research studies in key disease areas such as cancer, diabetes and neurological disorders. Through this collaboration, next generation sequencing technology will be made available to the European research and clinical communities through the Eastern Sequence and Informatics Hub at Addenbrooke’s Hospital in Cambridge.

11 Nov 2009

UIC receives federal grant to develop new antibiotics against anthrax, tularemia and plague

Researchers at the University of Illinois at Chicago have received a $4 million federal grant to develop new antibiotics to treat anthrax, tularemia and plague.

11 Nov 2009

Teva Pharmaceutical's generic lansoprazole does not infringe patent No. 5,464,632: U.S. Court

Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Takeda Pharmaceuticals North America, Inc.'s Prevacid® (Lansoprazole) SoluTab.

10 Nov 2009

Life Technologies to acquire BioTrove

Life Technologies Corporation, a provider of innovative life science solutions, today announced that it has signed a definitive agreement to acquire BioTrove, Inc. for an undisclosed amount.

10 Nov 2009

Aduro BioTech raises funds through its Series A-1 financing

Aduro BioTech, a privately held biotechnology company focused on the development of therapeutic and prophylactic vaccines based on proprietary recombinant strains of the bacterium Listeria monocytogenes, today announced completion of its Series A-1 financing.

10 Nov 2009

BioVex completes $70M financing to complete OncoVEX Phase III study

BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in addition to the $40 million announced in March. The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.

10 Nov 2009

Scarab Genomics reduces the E. coli K-12 genome, optimizing it for recombinant DNA and protein production

Scarab Genomics has made a series of planned, precise deletions to the E. coli K-12 genome, reducing the genome by more than 15%. The multiple-deletion series (MDS™) strains eliminate non-essential genes, cryptic virulence genes, and sequences of recombinogenic and mobile insertion sequence (IS) DNA, while preserving robust growth in rich and minimal media.

10 Nov 2009

Despite economic slowdown, Central and Eastern European countries still represent an attractive healthcare market

Despite the global economic decline, Central and Eastern European (CEE) countries such as Poland, the Czech Republic, Slovakia, Hungary, Bulgaria and Romania still represent an attractive healthcare market.

10 Nov 2009

NIH awards $6.8 million subcontract to Kineta to develop vaccine immune boosters

Kineta, Inc. announced today it has been awarded a $6.8 million subcontract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop novel vaccine adjuvants (agents that help boost the immune system). The Kineta subcontract is part of a larger $13 million award to the University of Washington.

10 Nov 2009

Baxter International lauds new Medicare education benefit for chronic kidney disease patients

Baxter International Inc. commends the Centers for Medicare and Medicaid Services (CMS) on announcing implementation plans for a new Medicare benefit that will provide Stage 4 chronic kidney disease patients with coverage for up to six sessions explaining their treatment options, such as transplantation, home peritoneal dialysis (PD), home hemodialysis (HHD) or clinic-based hemodialysis (HD).

From Baxter International Inc. 10 Nov 2009

Enavail obtains an exclusive license for a portfolio of particle engineering technologies

Particle engineering company Enavail announced today that it has obtained an exclusive license from The University of Texas at Austin for a portfolio of particle engineering technologies that will be utilized for pharmaceutical, biotechnology and nutraceutical applications.

10 Nov 2009

UCSD findings may help scientists to design better drugs to kill pathogenic strains

Over the last 20 years, the sequencing of the human genome, along with related organisms, has represented one of the largest scientific endeavors in the history of mankind. The information collected from genome sequencing will provide the raw data for the field of bioinformatics, where computer science and biology meet.

10 Nov 2009

Teva Pharmaceutical Industries amends patent infringement lawsuit against Momenta Pharmaceuticals/Sandoz

Teva Pharmaceutical Industries Ltd. announced today it is seeking to amend its existing complaint against Momenta Pharmaceuticals, Inc./Sandoz Inc. to include patent infringement of three additional patents related to the characterization of COPAXONE® (glatiramer acetate injection). The proposed updated complaint has been filed under seal with the U.S. District Court for the Southern District of New York along with a motion requesting that the Court grant Teva leave to amend.

10 Nov 2009

Biotechnology News and Research

Tobira Therapeutics presents data on TBR-652 at the European AIDS Conference

AVMA confirms that a household cat in Iowa showed signs of H1N1 influenza

Pacific Biosciences selects Camstar Manufacturing enterprise software to deliver innovative products

New biopharmaceutical business intelligence tool from Deloitte Recap

UK research funders announce support for a series of H1N1 2009 research projects

Vertex Pharmaceuticals announces exchange agreement with holders of its 4.75% Convertible Senior Subordinated Notes

Biopharma leaders to discuss optimized clinical operations and outsourcing strategies at iiBIG's forum

Cambridge based hub to use DNA sequencing platforms for advancing its targeted medical resequencing studies

UIC receives federal grant to develop new antibiotics against anthrax, tularemia and plague

Teva Pharmaceutical's generic lansoprazole does not infringe patent No. 5,464,632: U.S. Court

Life Technologies to acquire BioTrove

Aduro BioTech raises funds through its Series A-1 financing

BioVex completes $70M financing to complete OncoVEX Phase III study

Scarab Genomics reduces the E. coli K-12 genome, optimizing it for recombinant DNA and protein production

Despite economic slowdown, Central and Eastern European countries still represent an attractive healthcare market

NIH awards $6.8 million subcontract to Kineta to develop vaccine immune boosters

Baxter International lauds new Medicare education benefit for chronic kidney disease patients

Enavail obtains an exclusive license for a portfolio of particle engineering technologies

UCSD findings may help scientists to design better drugs to kill pathogenic strains

Teva Pharmaceutical Industries amends patent infringement lawsuit against Momenta Pharmaceuticals/Sandoz

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News